Forte Biosciences

Forte Biosciences

Forte Biosciences was founded in 2016 and went public via a reverse merger with Tocagen in 2020, retaining Paul Wagner as CEO. The company traces its origins to preclinical work at the University of California, San Diego, focused on commensal bacteria as immunomodulators. Unlike competitors pursuing systemic biologics, Forte committed early to a topical formulation — a decision that shaped its regulatory pathway and capital requirements. The firm's lead asset, FB-102, is a single-strain live biotherapeutic derived from Staphylococcus hominis A9. It targets atopic dermatitis and psoriasis by restoring a healthy skin microbiome. Forte has also explored graft-versus-host disease as a secondary indication. The company does not operate through traditional fund structures; it deploys capital raised in public markets and registered direct offerings into clinical trials and manufacturing scale-up. Geographic footprint remains US-focused, with trial sites concentrated in domestic academic medical centers. Forte runs lean — its registration statements have historically listed fewer than a dozen employees, relying heavily on contract research organizations and academic collaborators. In May 2024, the company announced a registered direct offering priced at-the-market under Nasdaq rules, raising gross proceeds of approximately $6 million to fund a Phase 2 trial for FB-102 in atopic dermatitis. No family-office co-investment vehicle, foundation, or club affiliation has been publicly reported. The structural differentiator is simplicity — Forte is a single-asset public biotech without a diversified pipeline or a parent family office. That concentration creates binary clinical risk but also eliminates the governance complexity of a multi-strategy healthcare platform. All scientific and capital-allocation decisions trace to Wagner, who holds both the CEO and Chairman roles, making the firm's strategic posture unusually linear for a Nasdaq-listed company.